Short Interest in Tivic Health Systems, Inc. (NASDAQ:TIVC) Decreases By 18.8%

Posted by Doug Wharley on Sep 29th, 2024

Tivic Health Systems, Inc. (NASDAQ:TIVC – Get Free Report) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totalling 81,400 shares, a drop of 18.8% from the August 31st total of 100,200 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,870,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Warberg Asset Management LLC acquired a new stake in Tivic Health Systems, Inc. (NASDAQ:TIVC – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 80,000 shares of the company’s stock, valued at approximately $31,000. Warberg Asset Management LLC owned 1.29% of Tivic Health Systems at the end of the most recent quarter. 4.25% of the stock is currently owned by institutional investors.

Tivic Health Systems Stock Performance

TIVC opened at $0.26 on Friday. Tivic Health Systems has a twelve month low of $0.23 and a twelve month high of $3.21. The firm’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.61.

Tivic Health Systems (NASDAQ:TIVC – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.32) earnings per share (EPS) for the quarter. Tivic Health Systems had a negative net margin of 606.47% and a negative return on equity of 172.08%. The company had revenue of $0.14 million during the quarter.

Tivic Health Systems Company Profile

(Get Free Report)

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.